Introduction
Cancer is a complex disease involving the activation of oncogenes and the inactivation of tumor/growth suppressor genes. Oncogenes believed to be involved in cancer have been identi®ed by a number of means including ampli®cation, chromosome translocation breakpoints, and in vitro transformation assays (Bishop, 1991) , while the identi®cation of tumor suppressor genes has relied heavily on the study of hereditary cancers and loss of heterozygosity studies (Devilee and Cornelisse, 1994) . Unfortunately, con®rmation of candidate tumor suppressor genes can be frustrating if a functional assay is not available. In vitro transfection studies have represented a standard method for con®rmation, but the high level of gene expression often created in transfection systems may not mimic the true eect of the gene product when present at physiological levels. The technique of microcell mediated chromosome transfer (MMCT) allows the introduction of a single copy of a gene into a recipient cell line due to the transfer of a single chromosome, followed by the analysis changes a cellular phenotype. The presence of a suppressor gene(s) is revealed by phenotypic changes in the growth of the recipient cell line. Diverse phenotypes may be obtained upon the introduction of dierent chromosomes into a cancer cell line, including, in vitro growth suppression, in vivo tumor suppression, and the induction of terminal dierentiation (Bader et al., 1991; Goyette et al., 1992) . Thus, the bene®t of introducing genes under the control of their own promoter and chromosomal environment, make MMCT a uniquely elegant method for assessing the role of gene products that are presumably expressed at normal physiological levels.
MMCT has been used to identify many chromosomes harboring in vitro growth suppressor activity as well as in vivo tumor suppressor activity (Bader et al., 1991; Goyette et al., 1992; Murakami et al., 1995; Negrini et al., 1994; Ning et al., 1991; Ohmura et al., 1995; Sandhu et al., 1996; Sasaki et al., 1994; Thiele et al., 1995) . The induction of in vitro growth suppression may represent replicative senescence. Cells undergoing replicative senescence remain metabolically active, but cease to proliferate (Vojta and Barrett, 1995) . Senescent cells that remain adherent to the growth surface may be maintained in this state for a number of weeks or months. Senescence phenotypes have been mapped to several chromosomes by MMCT, including chromosomes 1 and 18 in endometrial carcinoma cells, chromosome 4 in HeLa cells, and chromosome 6 in ovarian and breast carcinoma cells (Ning et al., 1991; Sandhu et al., 1996; Sasaki et al., 1994) . The eect of the introduction of chromosome 17 has varied by cell type, and these analyses have been complicated by the addition of wild type p53 to mutant p53 cell lines Goyette et al., 1992; Negrini et al., 1994) . The possibility of growth arrest induced by the introduction of a wild type copy of p53, has been dicult to separate from growth arrest induced by other chromosome 17 genes. The use of recipient cell lines that are wild type for p53, or the transfer of chromosome 17s deleted for p53 have also produced growth arrest in several dierent breast cancer cell lines implicating another growth suppressor gene on this chromosome (Casey et al., 1993; Murakami et al., 1995; Thiele et al., 1995) . In addition, chromosome 17 can induce in vivo tumor suppression in some cancer cell lines and this phenotype may represent the same or a dierent suppressor gene (Bader et al., 1991; Murakami et al., 1995; Negrini et al., 1994; Thiele et al., 1995) .
Human chromosome 17 contains a number of genes and loci believed to be involved in the pathogenesis of breast cancer. Four genes residing on chromosome 17 are known to be involved in breast cancer, p53, BRCA1, nm23, and Her-2/neu. The tumor suppressor gene p53 located on 17p13.1 is mutated in 15 ± 35% of sporadic breast cancers (Casey et al., 1996; Greenblatt et al., 1994) , and mutations in p53 may be associated with a poorer prognosis (Allred et al., 1993; Andersen et al., 1993; Saitoh et al., 1994; Thor et al., 1992) . Germline mutation of p53 leads to the development of multiple cancer types, including breast cancer, as part of the rare Li-Fraumeni cancer syndrome (Malkin, 1994) . The region of 17p distal to p53 (17p13.3) is believed to harbor one or more tumor suppressor genes based upon loss of heterozygosity (LOH) studies (Andersen et al., 1992; Stack et al., 1995) . One of these regions may represent a new candidate tumor suppressor gene on 17p13.3, HIC-1, which is hypermethylated and underexpressed in a number of breast cancer cell lines (Wales et al., 1995) . LOH analysis of sporadic breast tumors indicates at least one more tumor suppressor loci distal to HIC-1 (Andersen et al., 1992; Stack et al., 1995) .
Genes residing on 17q that are involved in breast cancer include the proto-oncogene Her2/neu (ERBB2) located at 17q12 which is ampli®ed in up to 35% of breast cancers. Ampli®cation is associated with poor prognosis, especially in lymph node positive patients (Slamon et al., 1989) . Mutations in BRCA1 located at 17q21 are thought to be reponsible for almost half of all inherited breast cancers (Easton et al., 1993) , but the role of BRCA1 in sporadic breast tumorigenesis is not clear. High rates of LOH at the BRCA1 locus have been reported in sporadic breast cancer (Futreal et al., 1992) , however, mutations in the BRCA1 coding region have not been described (Futreal et al., 1994) . Down regulation of BRCA1 expression or nuclear exclusion of the BRCA1 protein have been proposed as alternative mechanisms of BRCA1 inactivation in sporadic breast tumors Thompson et al., 1995) , but these results have not been con®rmed (Scully et al., 1996) . The candidate breast cancer metastasis suppressor gene, nm23 (located at 17q22), shows an inverse correlation between gene expression and metastasis in breast tumors (Bevilacqua et al., 1989; Tokunaga et al., 1993) . In addition, transfection of a nm23 gene into the highly metastatic breast cancer cell line MDA-MB 435, resulted in a signi®cant reduction in metastatic potential in vivo (Leone et al., 1993) . There is also functional evidence of a second metastasis suppressor gene on 17q. Studies have shown that MMCT of chromosome 17pter-q23 into rat mammary and prostate carcinoma cells results in suppression of metastasis, and this suppression was independent of nm23 expression (Rinker-Schaeer et al., 1994) .
At least four regions of LOH have been reported on chromosome 17q in sporadic breast tumors. One region of LOH lies proximal to BRCA1, as well as one region distal. Two more regions of LOH have been found on distal 17q, de®ned approximately by markers CMM86 (D17S74), and THH59 (D17S4) (Cropp et al., 1993; Cropp et al., 1994; Devilee and Cornelisse, 1994; Kirchweger et al., 1994; Nagai et al., 1994) . We have recently performed extensive LOH studies of chromosome 17q on 85 breast tumor/normal pairs, and report a region of allelic imbalance proximal to BRCA1, as well as three regions more distal on 17q22-qter (SJ Plummer et al., submitted).
We have previously shown that the introduction of a human chromosome 17 into the MCF7 breast cancer cell line results in growth arrest within 8 weeks (Casey et al., 1993) . We have reported that MCF7 is structurally wild type for p53, and more importantly, that the overexpression of a wild type p53 transgene is compatible with the normal growth of MCF7 cells (Casey et al., 1991) . In addition we have shown that the MMCT of a normal human chromosome 13 has no eect on MCF7 cells in vitro or in vivo implying the presence of a novel growth suppressor gene on chromosome 17. In this study we report the transfer of a series of neo r chromosome 17 deletion hybrids into MCF7 cells and the localization of the MCF7 growth suppressor activity to chromosome 17q24-q25.
Results

Creation of a chromosome 17 deletion hybrid panel
Deletion hybrids were created by taking advantage of the natural breakage that occurs in approximately 30% of chromosomes transferred by MMCT. The original neomycin resistant (neo r ) chromosome 17 hybrid 313.4, was transferred into a new recipient mouse A9 cell line, and the resulting neo r clones were tested for the retention or loss of a series of human chromosome 17 speci®c short tandem repeat (STR) markers. Clones demonstrating a deletion in a region of interest were further characterized by a larger panel of 77 STRs (SJ Plummer et al., submitted), and cytogenetic analysis. Potential deletion hybrids were analysed by¯uorescence in situ hybridization (FISH) with a total human DNA probe. FISH analysis revealed that approximately 50% of the chromosomes containing deletions were single intact human chromosomes.
d43 chromosome suppresses MCF7 growth in vitro and excludes p53 as a candidate gene Chromosome 17 hybrid d43/A9 is deleted for 17p13.1-pter, including loss of p53, HIC-1, and the distal 17p13.3 region identi®ed by LOH studies (Figure 1) . Introduction of this hybrid into MCF7 breast cancer cells results in growth arrest of the clones within 8 weeks following transfer, similar to that seen when a complete chromosome 17 is introduced (Casey et al., 1993) . Whereas neo r colonies are morphologically indistinguishable from the parental MCF7 cells prior to growth arrest, arresting cells appear to¯atten and detach from the¯ask surface (Figure 2 ) (Casey et al., 1993) . Vigorously growing clones may also be present 17q24-q25 breast cancer growth suppressor gene SJ Plummer et al which eventually overgrow any remaining growth arrested colonies. Thirty four d43/MCF7 revertants were selected for analysis for the retention of the introduced chromosome 17. A panel of chromosome 17 short tandem repeat (STR) polymorphic markers was chosen (3 from 17p and 6 from 17q) that distinguish the MCF7 chromosome 17 allele from the introduced chromosome 17 allele. Analysis of revertants with this panel of STR markers revealed that only 24% of the revertants retained all nine STR markers tested ( Table 1 ). Revertants that retained all nine markers are assumed to contain microdeletions not detectable with our panel of markers, or to have inactivated the growth suppressing gene by other mechanisms. Twenty-nine per cent of the revertants had deletion of all of the markers tested, suggesting loss of the entire chromosome except for the neo r gene. Fortyseven per cent of the clones demonstrated a complex pattern of deletion in the introduced chromosome (Figure 3) .
To further localize the growth suppression phenotype, we transferred hybrid d26/A9, which is deleted for all of the chromosome 17p arm, while retaining all of the q arm (Figure 1 ). This hybrid suppressed growth in the same manner as the whole chromosome 17 hybrid 313.4, and the d43/A9 hybrid. The d26/A9 hybrid was shown to contain a human/mouse translocation chromosome, unlike all other hybrids used in this study which contained a single intact human chromosome. The in vitro growth suppression caused by this hybrid provides support that the growth suppression gene resides on chromosome 17q. Hybrids d2/A9 and d624/A9 have overlapping deletions in 17q24-q25 (Figure 1) . MMCT of each of these chromosomes resulted in normal growth and morphology of the expanded neo r clones. STR analysis was performed on these clones, and the majority of hybrids retained an intact chromosome (Table 1, Figure 4 ). d624/ MCF7 hybrids retained the introduced chromosome in 69% of the clones, while d2/MCF7 hybrids retained it in 73%. This frequency of approximately 30% breakage of the introduced chromosome is consistent with the level of breakage that we observe following transfer of a chromosome 17 into A9 cells. Individual loci were deleted in 4 ± 25% of the d2/MCF7 and d624/MCF7 hybrids tested. No preferential loss of marker D17S855 was found. D17S855 is intragenic to BRCA1, and this result supports the exclusion of BRCA1 as the gene responsible for the growth suppression of MCF7 cells by chromosome 17. Importantly, clones that appeared to retain all of the markers were also shown to have an intact chromosome by chromosome 17 FISH painting (data not shown).
Discussion
We have previously described the in vitro growth suppression of MCF7 cells following the introduction of a normal chromosome 17 by MMCT (Casey et al., 1993) . We have suggested that this represents the presence of a growth suppressor gene on chromosome 17. MMCT has been used to identify chromosomes carrying genes responsible for many cellular phenotypes (Bader et al., 1991; Goyette et al., 1992; Murakami et al., 1995; Negrini et al., 1994; Ning et al., 1991; Ohmura et al., 1995; Sandhu et al., 1996; Sasaki et al., 1994; Thiele et al., 1995) . However, there have been few studies that have attempted to further localize the genes responsible for these phenotypes. We have localized the MCF7 growth suppressor function by the introduction of chromosome 17 deletion hybrids into MCF7 cells. We chose to create deletion hybrids through the low level random breakage that occurs following transfer of chromosomes by MMCT. Rigorous molecular and cytogenetic analyses were subsequently performed to fully characterize these deletion chromosomes. Undetected microdeletions, or multiple areas of deletions may occur in some hybrids and we have therefore recommended the use of multiple overlapping deletion hybrids to con®rm phenotypic eects. Alternative methods have been used in other studies for the subchromosomal localization of suppressor genes, including deletion mapping of revertant clones (Murakami et al., 1995; Negrini et al., 1994; Sandhu et al., 1996) , as well as MMCT of deletion hybrids created by irradiation (Dowdy et al., 1990; Koi et al., 1993; Murakami et al., 1995; Reid et al., 1996) . However, the presence of chimeric fragments, transfer of mouse genes, and the possibility of radiationinduced mutations may compromise the results obtained by these methods.
We have previously shown that MCF7 cells are wild type for p53 by sequence analysis of the entire coding region (exons 2 through 11) (Casey et al., 1993) . In addition we have shown that MCF7 cells are unaected by the overexpression of a wild type p53 cDNA, unlike mutant p53 cancer cell lines that cannot support the expression of an introduced wild type p53 gene (Casey et al., 1991) . The growth suppression that we observe with the introduction of the d43/A9 hybrid, which is deleted for 17p13, is compatible with our exclusion of p53, and also excludes other genes on chromosome 17p13 including HIC-1 and the candidate 17p13 tumor suppressor gene(s) de®ned by LOH. In addition, analysis of hybrid clones resulting from the transfer of d2/A9 and d624/A9 into MCF7 do not show any preferential loss of the p53 region of the introduced chromosome 17. Negrini et al. found that the introduction of a human chromosome 17 into MCF7 cells by MMCT did not produce viable clones, and concluded that this was the result of introducing a wild type p53 gene into these cells (Negrini et al., 1994) . In their study, they showed that p53 protein was excluded from the nucleus. They were also unable to express wild type p53, obtaining only rearranged clones upon transfection of a wild type p53 transgene, concluding that wild type p53 was not compatible with growth of these cells. These results are clearly contrary to our data. We suggest that the discrepancy between these data and ours may be due to dierent MCF7 sublines being used by the two groups. For example, three MCF7 sublines obtained from dierent sources showed varied biological properties, such as estrogen and progesterone receptor levels, as well as cloning eciency, but appeared to be derived from a common precursor cell (Osborne et al., 1987 ). An inherent genetic instability was suggested as a mechanism responsible for subline dierences (Osborne et al., 1987) . Whether or not this represents the basis for the dierence in p53 results between the two groups, it should be noted, that the results obtained by Negrini et al. are compatible with our localization of a growth suppressor gene to 17q24-q25.
d2/A9 and d624/A9 hybrids did not suppress the growth of MCF7 cells, indicating that the gene responsible for the growth suppression phenotype is located in the overlapping region of deletion at 17q24-q25. This data excludes BRCA1 (17q21) as the gene responsible for this phenotype, additionally supported by the lack of preferential loss of D17S855 in our d/MCF7 clones. D17S855 is located within an intron of BRCA1, and would be expected to be deleted in a large proportion of hybrid clones if BRCA1 were responsible for the growth inhibition. Holt et al. have shown that introduction of a wild type BRCA1 gene into MCF7 cells by retroviral infection results in the in vitro and in vivo suppression of growth which is contrary to our ®ndings. Our data suggests that the introduction of an additional single copy of BRCA1 into MCF7 cells has no eect on in vitro growth. We suggest that the in vitro growth suppression observed by Holt et al. may be occurring due to the high level of expression of BRCA1 from their retroviral constructs. This is supported by the evidence that they were able to overcome in vitro growth arrest by growing their cells in enriched media, a result that we have been unable to achieve with our growth arrested MMCT clones. The possibility still exists that BRCA1 may suppress the tumor growth of MCF7 cells in vivo.
Most cell types derived from higher eukaryotes have a ®nite life span, and cease to divide by a process termed replicative senescence. It has been proposed that senescence may represent a form of tumor suppression in vivo (Campisi, 1996; Vojta and Barrett, 1995) . A potential mechanism for the`counting' of cell divisions is the reduction of telomere length that has been correlated with decreasing replicative life span (Allsopp et al., 1992) . Immortal cells retain telomere length through the activity of a telomerase enzyme complex (Counter et al., 1992) . A recent study has reported that the introduction of chromosome 3 by MMCT into a renal carcinoma cell line results in decreasing telomere length, the inhibition of telomerase activity and the inhibition of cellular proliferation (Ohmura et al., 1995) . The irreversible growth arrest found in replicative senescence is a separate phenotype from apoptosis, but the relationship between terminal dierentiation and senescence is not clear (Campisi, 1996; Vojta and Barrett, 1995) . We do not know whether the MCF7 in vitro growth suppression that we observe following the introduction of chromosome 17 represents replicative senescence, or another growth control mechanism. The delay that occurs before growth arrest may indicate an inhibition of a telomerase activity and therefore telomere shortening. However, an alternate mechanism of delayed growth arrest could be the induction of dierentiation, an example of which was found upon the MMCT of chromosome 1p into a neuroblastoma cell line (Bader et al., 1991) . The cloning of the MCF7 growth suppressor gene will enable these mechanisms to be directly tested.
We have shown that the MCF7 growth suppressor activity is localized to the region deleted in hybrids d2/ A9 and d624/A9, at 17q24-q25. A high resolution radiation hybrid map of this region indicates that the overlapping deletion from these two hybrids is approximately 3.8 Mb (Foster et al., 1996) . The transfer of additional hybrids with deletions in this region should allow further delineation of the region containing the growth suppressor gene, followed by positional cloning to determine the gene responsible for the growth suppression phenotype.
Materials and methods
Cell lines and microcell mediated chromosome transfer (MMCT)
The recipient MCF7 breast cancer cell line was originally obtained from Dr CM McGrath. The MMCT donor cell line, 313.4, contains a human chromosome 17 in a mouse A9 background, with integration of a neo r gene at 17q25 (Leach et al., 1989) . MMCT was performed as described (Casey et al., 1993) . All MMCT experiments were performed in duplicate, and a minimum of ten dierent experiments were performed for each deletion hybrid introduced into MCF7. No more than three colonies were chosen from each plating for detailed analysis, to reduce the possibility of analysing sister clones.
Molecular and cytogenetic analysis of MMCT clones
Deletion hybrids were analysed by FISH with¯uorescent labeled total human DNA according to manufacturer's instructions (Oncor). Representative MCF7 MMCT clones were tested by chromosome 17 FISH painting following manufacturer's instructions (Vysis). Genomic DNA for short tandem repeat (STR) analysis was obtained by Proteinase K digestion followed by phenol extraction, or by use of a spin column procedure (Qiagen). Oligos for STR analysis were obtained from Genosys Biotechnologies or Research Genetics. Sequence of oligos are available from the Genome Database (GDB;http:// gdbwww.gdb.org). PCR buer consisted of 67 mM TrisHCl pH 8.8, 6.7 mM magnesium chloride, 16.6 mM ammonium sulfate, 10 mM b-mercaptoethanol, 12.5 mM each dNTP, and 10% DMSO. STR products of the A9 MMCT clones were analysed by electrophoresis on 6% nondenaturing acrylamide gels, followed by ethidium bromide staining. All STR products used in polymorphic analysis of the MCF7 MMCT clones were analysed by this method, with the exception of D17S855. D17S855 was analysed using a 32 P-end-labeled oligo, followed by separation on a 6% denaturing gel, and phosphorimager detection (Molecular Dynamics).
